Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Sang Kyu Cho(University of Southern California), Scott Johnson, Suchin Virabhak, Kavita Sail(AbbVie (United States)), Hélène Parisé, Matthew S. Davids(Dana-Farber Cancer Institute), Beenish S. Manzoor(AbbVie (United States)), Arliene Ravelo(Dana-Farber Cancer Institute), Simon Sharmokh(AbbVie (United States)), Sheila Shapouri(Dana-Farber Cancer Institute), Tatyana Kapustyan(AbbVie (United States))
Cited by 19
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595